Q3 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
ScemblixⓇ sales grew across all regions, demonstrating
the high unmet need in CML
Sales evolution
USD m
Ex-US
US
+157%
106
33
41
4
73
37
Q3 2022
Q3 2023
GROWTH
SCEMBLIX®
(asciminib) 20 mg, 40 mg tablets
"
Q3 sales reflect continued demand from patients with
Ph+ CML-CP resistant or intolerant to 2 or more prior TKIs
Leading market share 3L+ in US (NBR× 34%, TRX 20%)
■ Global rollout ongoing with strong performance in Japan and France
■ >40% of patients not satisfied with side effect profile of 1st and 2nd
generation TKIs, highlighting need for more tolerable treatments1
▪ ASC4FIRST (1L registrational study) readout and filing expected 2024
Ph+ CML-CP - Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. 1. Survey on unmet needs in CML at EHA: reveals the need for treatment decisions that balance quality of life, efficacy, and tolerability goals;
Chronic Myeloid Leukemia Survey on Unmet Needs (CML SUN).
13 Investor Relations | Q3 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation